The American Cancer Society Cancer Action Network (ACS CAN) is pleased to see President Biden’s continued focus on and dedication to achieving the goal of the Cancer Moonshot to end cancer as we know it, for everyone.
The Biden Cancer Moonshot announced today the expansion of coverage for patient navigation services in plans from seven health insurance companies.
WASHINGTON, DC — 7 de marzo de 2024 — Antes del discurso del presidente Biden sobre el Estado de la Nación, la Red de Acción Contra el Cáncer de la Sociedad Americana Contra el Cáncer (ACS CAN, por sus siglas en inglés) insta al presidente a enfatizar la necesidad de un continuo apoyo bipartidista para aumentar la inversión federal para la investigación del cáncer en los Institutos Nacionales de la Salud (NIH, por sus siglas en inglés) y el Instituto Nacional del Cáncer (NCI, por sus siglas en inglés), así como el financiamiento de programas de prevención en los Centros para el Control y la Prevención de Enfermedades (CDC, por sus siglas en inglés). Además, ACS CAN insta al presidente a finalizar sin demora la normativa de la Administración de Alimentos y Medicamentos (FDA, por sus siglas en inglés) que prohíbe la venta de mentol en los cigarrillos.
Milwaukee attorney Philip R. O’Brien has accepted the role of Cancer Votes National Ambassador for the American Cancer Society Cancer Action Network (ACS CAN), the advocacy affiliate of the American Cancer Society (ACS). This role is an expansion of O’Brien’s current commitment to ACS CAN as a member of its national Board of Directors since 2019. Cancer Votes is ACS CAN’s nonpartisan electoral program, a public education avenue through which cancer issues are elevated as a key priority during election cycles. As National Ambassador, Phil O’Brien will serve as a brand leader, seeking to draw high levels of engagement from volunteers, the media and the advocacy and business communities.
Today, the U.S. Court of Appeals for the Fifth Circuit will hear oral arguments in Braidwood Management v. Becerra, a case that threatens access to evidence-based preventive services without cost-sharing as required under the Affordable Care Act (ACA). The services at-risk include those recommended by scientific experts at the U.S. Preventive Services Task Force (USPSTF), the Advisory Committee on Immunization Practices (ACIP) and the Health Resources and Services Administration (HRSA).
A new paper released today in the Journal of Clinical Oncology finds that while incorporating pharmacogenomic (PGx) testing into cancer care can help improve patient outcomes, barriers to PGx testing, discovery, and implementation are impacting its adoption and creating disparities that impact diverse populations.
Dr. Christina Annunziata, the Senior Vice President of Extramural Discovery Science at the American Cancer Society, testified today before the House Committee on Energy and Commerce’s Subcommittee on Health in support of the Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act and the Women and Lung Research and Preventive Services Act.
Protecting free preventive cancer screenings and reducing the burden of medical debt are the top issues of concern for cancer patients and survivors today, according to a new survey by the American Cancer Society Cancer Action Network (ACS CAN) that asked participants to select their leading policy priorities for the year.
Today, the American Cancer Society Cancer Action Network (ACS CAN) issued a letter to the National Institutes of Standards and Technology (NIST) commenting on the utilization of march-in rights (MIR) to lower prescription drug costs following the release of new guidance by the administration on its application.
WASHINGTON, DC – Hoy, la Red de Acción Contra el Cáncer de la Sociedad Americana Contra el Cáncer (ACS CAN) se unió a otras 20 organizaciones para proponer que la Oficina del Inspector General de Salud y Servicios Humanos adopte una disposición de protección regulatoria (puerto s